{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-22-000091","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.239921+00:00","generated_at":"2026-06-22T09:00:25.293884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Guardant Health Q3 revenue $117.4M (+24% YoY); cuts full-year revenue guidance to $440-450M","bullets":["Q3 clinical test volume 32,400 (+42% YoY); biopharma tests 6,750 (+40% YoY).","GAAP net loss per share -$1.58; non-GAAP -$1.18; Adj. EBITDA loss -$112.8M.","Full-year 2022 revenue guidance lowered to $440-450M from $460-470M, citing challenging backdrop.","FDA approved Guardant360 CDx as companion diagnostic for ENHERTU in HER2-mutant NSCLC.","ECLIPSE readout and Shield PMA submission expected in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-22-000091","json":"https://secwatch.observer/filing/0001576280-22-000091.json","markdown":"https://secwatch.observer/filing/0001576280-22-000091.md","text":"https://secwatch.observer/filing/0001576280-22-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/0001576280-22-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/gh-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:00:25.293884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f16dd11e8782edfd94d8f13bdc0c0cf2861ce3","claim":"Guardant Health, Inc. reported the quarter ended September 30, 2022 results: revenue $117.4 million, net income $162.0 million, EPS $1.58. Guidance lowered.","evidence_excerpt":"use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021 • Reported 32,400 tests to clinical customers and 6,750 tests to biopharmaceutical","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/0001576280-22-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$117.4 million"},{"label":"Net income","value":"$162.0 million"},{"label":"EPS","value":"$1.58"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}